Government issues rallying cry to the nation to help fix NHS: Members of the public as well as NHS staff and experts will be invited to share their experiences views and ideas for fixing the NHS
Comment: The NHS remains one of the biggest Socialist follies of the post-war era, something which apart from being a infinite financial black hole, is a second rate service at a first class cost, a major reason for lockdown, and the bringer of dozens of scandals and disasters. It is appropriate that 75 years on we have another disastrous Socialist government, issuing a cry for help.
GreenRoc Strategic Materials (GROC), a company focused on the development of critical mineral projects in Greenland, announced that Stefan Bernstein, Chief Executive Officer, will be recording an Investor Presentation and Shareholder Q&A session. The recording will be published on the Company’s website and the London South East investor platform at https://www.lse.co.uk/media/GROC/on Monday 28 October 2024.
Comment: This Q&A is well timed in the sense that it comes in the wake of last month’s news that it has submitted its application for an Exploitation Licence for the Amitsoq Graphite Project in South Greenland. Shareholders are likely to be keen on knowing the timelines as far as the development of Amitsoq into a producing mine.
Audioboom (BOOM), the global podcast company, announced that Michael Tobin OBE, non-executive Chairman of the Company, purchased 10,620 ordinary shares in the Company on 18 October at a price of 215 pence per ordinary share. Following this purchase, Michael Tobin holds 850,000 ordinary shares in the Company, representing approximately 5.2 per cent. of the Company’s issued share capital.
Comment: An excellent update from Audioboom last week, but not enough to get the share price up, as whoever is selling the stock on any strength towards 250p continues to do so. They are clearly selling / shorting more than the 10,620 shares that Mr Tobin has just bought as part of his merit worthy averaging down strategy.
Ananda Developments plc (AQSE: ANA) announced that two of its patent pending cannabinoid medicines, MRX2 and MRX2T, will be used in two National Institute for Health and Care Research (NIHR) and NHS co-funded Phase IIIa epilepsy clinical trials involving up to 500 patients in total. The trials will be run by investigators at University College London and Great Ormond Street Hospital. ANA said the UK Government and the NHS have made it clear they need to see randomised controlled trials in a broad range of seizure types and epilepsies to enable wide prescribing of CBD- and THC-based medicines. Its clear objective is to deliver licensed CBD-based medicines which will be available on the NHS.
Comment: As far as counterparties and validation, it does not get better than the NHS, UCL, GOSH et al. We have further proof, if it was required, that ANA is going to deliver for the NHS, and more importantly provide powerful new treatments.
Helix Exploration (HEX), the helium exploration and development company focused on helium deposits within the ‘Montana Helium Fairway’, provided an operational update on the Clink #1 well at the Ingomar Dome Project. HEX said the successful re-entry and subsequent deepening of Clink #1 is a significant milestone for the Company. It was delighted with the re-entry efforts and the exceptional work of its engineering team, as it sees promising results in each of the target formations.
Comment: HEX is certainly back on track at Clink #1, with the deepening of the asset meaning that we are looking to the results in terms of helium finds sooner, rather than later.
EnergyPathways (EPP), an energy transition company developing low carbon integrated energy solutions in the UK, advised that Department of Energy Security and Net Zero (DESNZ) has invited EnergyPathways to participate in the Hydrogen Storage Business Model (HSBM) Design Group. This group comprises a select number of companies, including several Tier-One companies that are at the forefront of the UK’s energy transition.
Comment: Today’s announcement from EPP explains why at the end of last week there were some significant buy trades going through. Presumably some traders successfully guessed today’s news was on its way. By the way the stock was mentioned, in the wake of the buying in yesterday’s Bulletin Board Heroes.
Castillo Copper (CCZ), a base metal explorer primarily focused on copper across Australia and Zambia, announce it has entered into a binding agreement with Audax Holdings Pty Ltd (ACN: 678 403 864) to acquire 85% of the highly prospective Harts Range Niobium, Uranium and Heavy Rare Earths Project via an earn-in arrangement.
Comment: It is always interesting when an explorer with already highly prospective assets to develop to production, buys some more. Perhaps some investors would be happier if they focussed on what is already on their plate?
XLMedia (XLM), a sports digital media company, announced that it has entered into a conditional asset purchase agreement for the sale of certain assets that constitute the Company’s North America Business to Sportradar AG. Conditional agreement to dispose of the North America Business for up to $30.0 million in cash: $20.0 million payable on Completion; and up to an additional $10.0 million payable in April 2025, subject to performance.
Comment: It is a testament to the degree of comms from XLM that all but its most loyal shareholders are likely not to have known that the company was sitting on assets worth up to $30m. The stock market is perhaps not the best place to hide one’s light under a bushel.
Sound Energy (SOU), the transition energy company, confirmed the receipt of formal approval from the Moroccan Minister of Energy Transition and Sustainable Development to SEME continuing as the Operator of record of the Tendrara Exploitation Concession, and the Anoual and Grand Tendrara Exploration Permits, following completion of the Transaction.
Comment: It would appear that SOU is doing rather better with the Moroccan authorities in terms of getting the green light than Emmerson (EML).
Altona (REE), a resource exploration and development company focused on diversified critical raw materials in Africa, announced the results of the geophysical and geochemical data assessment for the Company’s new Kabompo South copper project in Zambia, performed by Earthmaps Consulting.
Comment: Fresh from the recent Goldman Sachs grade research note on the company, we have a “very positive” data assessment carried out by Klaus and his team has clearly outlined a geological context favorable to IOCG mineralisation, which are known to carry viable copper deposits in Zambia. Of course, the two events are not linked. That said, Cedric and the team have always appeared to be fully capable of proving up assets.
Light Science Technologies (LST), comprising three divisions: Controlled Environment Agriculture; Contract Electronics Manufacturing ; and Passive Fire Protection, announces a significant follow on order from an existing customer in its PFP division, worth £1.17m.
Comment: LST underlines the fact today that with today’s news of a significant contract, that with three growing divisions, three cylinders to fire on, and all of them can be company makers.
Deltic Energy (DELT), the AIM quoted natural resources investing company, provided a strategic, operational and organisational update. DELT said its immediate focus is the ongoing Selene exploration well, where initial drilling indications are encouraging. As always, the balance of geological, operational and political risk must be considered and it is actively assessing a number of attractive opportunities in geographies where more supportive policies towards oil and gas development exist.
Comment: Canacord as broker is clearly an upgrade for DELT, and it can be seen that the company is still working out how to put its best foot forward in the current somewhat challenging environment for its sector after the change of CEO.
EnSilica (ENSI), a chip maker of mixed signal ASICs, announced that it has been awarded an ASIC design services contract with a prestigious supplier of power and propulsion systems used in the air, at sea, and on land. The c.£2 million Contract will commence in November 2024, with revenues to run into the Company’s next financial year, supporting market expectations for both those periods.
Comment: Having been described here at the RNS Hotlist as the UK’s answer to Nvidia, it is only fitting that ENSI keeps on winning contracts such as the one announced today.
EnQuest (ENQ), an independent oil and gas production and development company, announce it has been awarded the DEWA Complex Cluster Small Field Asset Production Sharing Contract in partnership with Petroleum Sarawak Exploration & Production Sdn Bhd and Longboat Energy by Petroliam Nasional Berhad through Malaysia Petroleum Management (MPM). ENQ said the block contains several undeveloped discoveries providing future opportunities for EnQuest to demonstrate its proven capabilities in innovative and cost-effective development. We would like to thank PETRONAS for their confidence in awarding us this PSC and are pleased to have our first joint venture with PSEP.
Comment: ENQ has done rather better than some rather smaller UK companies in its space and geography in getting a PSC, and one that looks to be significant.
Avacta Therapeutics (AVCT), a life sciences company, announced the initiation of an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc. (Nasdaq: TEM), a technology company leading the adoption of artificial intelligence to advance precision medicine and patient care.
Comment: AVCT is clearly going for it in terms of getting RNS releases out there which could potentially get the shares over the 70p level, where it would appear that someone continues to sell the shares quite aggressively. Perhaps the AI infused news today will help, although of late the pipeline expansion is the key near term.
Tristel (TSTL), the manufacturer of infection prevention products for hospitals, announces its audited preliminary results for the year ended 30 June 2024, with trading ahead of both market expectations and internal performance targets. The Company has delivered record revenues, growth in pre-tax profits and maintained strong cash generation from the operations. It continues to be debt free and at the end of year cash and short-term investments balances were £11.8m including £5.7m held as short-term investments.
Comment: Trading ahead of market expectations in the present environment deserves some kind of medal, although given the hospitals space it occupies, such an achievement must be rather easier to achieve than most.
Cizzle Biotechnology (CIZ), the UK based diagnostics developer, announced that it has signed an exclusive licensing and partnership agreement for its proprietary CIZ1B biomarker test to help detect early-stage lung cancer, throughout the USA and Canada This is the critical first step in the Company’s global licensing and partnership strategy to bring Cizzle’s non-invasive, cost effective CIZ1B biomarker lung cancer blood test to market next year.
Comment: After going somewhat quite, CIZ reminds us that not only is it on fire in North America, but has global licensing potential, which could finally lift the stock off current lowly levels.
Nativo Resources (NTVO), which has interests in precious metals mining and production in Peru, updated on the Tesoro Gold Concession, in southern Peru, which is held by the Company’s 50%-owned Peruvian joint venture, Boku Resources SAC. NTVO said Tesoro continues to be an extremely exciting project for Nativo. It was pleased to report on high-grade assay results of initial vein material recovered from Bonanza, with findings demonstrating impressive grades of up to 27g/t.
Comment: The old Echo Energy seems to be gathering momentum after the name change, something which shareholders may start to appreciate rather more after today’s promising announcement.
Allergy Therapeutics (AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that the first subjects have been screened and enrolled in the Group’s Phase III G308 trial to evaluate the long-term efficacy and safety of Grass MATA MPL in paediatric subjects.
Comment: Phase III is always a big deal in biotech, and this explains the recent strong run for AGY shares, which one would now expect to continue in earnest.
Author
